|Rapid review complete
|For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic assessment recommended at the submitted price
The HSE has approved reimbursement following confidential price negotiations; April 2018.